• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Prognostic factors affecting survival in multiple myeloma].

作者信息

Tornóczky J, Tóth A, Sziládi E, Hoffmann E, Liszátz M

机构信息

Megyei Kórház-Rendelöintézet Szekszárd, IV. sz. Belgyógyászati Osztály.

出版信息

Orv Hetil. 1990 Aug 5;131(31):1679-84.

PMID:2205822
Abstract

70 patients suffering from multiple myeloma were observed by authors in the last 15 years and three months. In the meantime fifty-two out of them have died, and 18 patients are under permanent care. 43 IgG, 17 IgA, 6 Bence-Jones, 2 IgD types were diagnosed according to the paraprotein distribution, one patient proved to be nonsecretory, and an other one to osteosclerotic form as well. The median survival time was 27 months in the group of deceased patients. In the group followed-up 50.8 months survival time was observed up to the closing of the study. Several prognostic factors were investigated. According to the classification by Durie and Salmon the survival time was 60 months in the patients with stage I, 33 months in stage II., and 9 months in stage III respectively. The prognosis is much poorer in patients into the "B" category: the survival time was 14 months. Classified in the basis of the type of the myeloma-cell, the cases with well matured cells have had the best prognosis with survival time of 46 months, while the most unfavourable prognosis was observed in patients with blast-cell type, with a median survival time of 10 months. The greatest number of patients suffered from multiple myeloma of IgG paraprotein type, in this group the serum IgA level was found to be significantly decreased in the patients died due to inevitable infections. The survival was injured significantly by the occurrence of concomitant severe diseases, to.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
[Prognostic factors affecting survival in multiple myeloma].
Orv Hetil. 1990 Aug 5;131(31):1679-84.
2
[BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].[血尿素氮、本周氏蛋白和染色体畸变可预测多发性骨髓瘤的生存率]
Rinsho Ketsueki. 1997 Dec;38(12):1254-62.
3
[Isotypic characterization of IgA paraproteins: association with other clinical and analytic data].[IgA副蛋白的同型特征:与其他临床和分析数据的关联]
Rev Clin Esp. 1996 Aug;196(8):529-35.
4
IgD multiple myeloma. A report of three cases.IgD型多发性骨髓瘤。三例报告。
Minerva Med. 1996 Mar;87(3):109-12.
5
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.多发性骨髓瘤的自体干细胞移植:非分泌型多发性骨髓瘤患者生存率提高,但年龄、移植时状态、既往治疗及预处理方案无影响。127例患者的单中心经验
Bone Marrow Transplant. 2003 Feb;31(3):163-70. doi: 10.1038/sj.bmt.1703818.
6
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.接受序贯治疗的本-周氏蛋白、IgG和IgA骨髓瘤新患者的比较:需要将这些免疫亚型视为具有特定预后标准的独立疾病实体。
Bone Marrow Transplant. 2001 Jul;28(1):29-37. doi: 10.1038/sj.bmt.1703093.
7
[Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].[骨多发性骨髓瘤。基于243例患者的系列研究对预后因素的回顾性分析]
Rev Rhum Mal Osteoartic. 1979 Feb;46(2):77-83.
8
Prognostic factors and therapeutic results in multiple myeloma.
Jpn J Clin Oncol. 1985 Sep;15(3):505-15.
9
[Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
Minerva Med. 1987 May 15;78(9):603-8.
10
Correlation of abnormal immunoglobulin with clinical features of myeloma.异常免疫球蛋白与骨髓瘤临床特征的相关性
Arch Intern Med. 1975 Jan;135(1):46-52.